News About: R&D


‘Artificial Intelligence’ over hypothesis-driven study

An opinion was raised that development of new drugs must go towards AI, not the conventional hypothesis-driven studies. At the ‘Artificial Intelligence, New Paradigm of New Drug Development’ seminar on the 7th, Profe...

Hanmi Pharm’s new oral anticancer drug ‘Oraxol starts global Phase III clinical trial

They will actively start the global Phase III clinical trial of Oraxol, an oral anticancer drug developed by Hanmi Pharm. A Hanmi Pharm’s partner, Athenex(Nasdaq: ATNX) announced that the company completed the Phase ...

Government to impose disciplinary fine for falsely reporting adverse drug reactions in clinical trials

If an institute or organization is exposed for a false report of adverse drug reactions during a clinical trial, a disciplinary fine will be imposed. In order to keep patients participating in clinical trials safe an...

Curatis starts 2a clinical trial of adult tuberculosis vaccine this January

Curatis, an immune vaccine and immunotherapy company, announced to conduct a Phase 2a clinical trial of tuberculosis preventive vaccine for adults at Yonsei University Severance Hospital this January. The company acqu...

Seegene succeeds in developing reagents using AI for the first time

Seegene succeeded in developing a molecular diagnosis reagent only in 4 days with its self-developed automated AI reagent development system. Seegene(CEO Jong-Yoon Chun), a molecular diagnosis company, announced on t...

Oscotec applies for U.S. clinical 2a IND of its rheumatoid arthritis treatment

Oscotec(CEo Jung-Geun Kim), a new drug developing company, announced on the 26th that the company applied for a IND for a clinical 2a study to the U.S. FDA as completing Phase I SAD(single ascending dose) & MAD(multip...

KPBMA establishes private-public AI Novel Drug Development Support Center by 2019

The ‘Artificial Intelligence(AI) Novel Drug Development Support Center’ jointed established by private and public organizations will be launched in 2019 in Korea, which attract attention of the pharmaceutical industry...

Kuhnil first reveals Phase III clinical trial for Omega-3 & Rosuvastatin combination drug

Kuhnil(CEO Young-Joong Kim) announced the Phase III clinical trial result for ‘Rosumega SC,’ a dyslipidemia combination drug, was published in the SCI-level international journal ‘Clinical Therapeutics’ on 6 December....

Foreign CROs hot in Korea, accounting for more than 30% of total CROs in Korea

In the Korean clinical study market, foreign CROs(contract research organization) are reportedly getting popular. According to the ‘Korea Clinical Trail Industry Statistics’ published by the Korea National Enterprise...

Korea follows only 71.4% of U.S. drug development technology

It was analyzed the Korea’s technological level of drug development was 71.4% of what the U.S. had and the technological gap was 4.1 years. The Ministry of Health and Welfare and the Korea Health Industry Development...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.